| INTRODUCTION
In the United States, prostate cancer is the second leading cause of cancer related deaths and the most commonly diagnosed cancer in men with an estimated 220 800 new cases yearly. 1, 2 Androgen deprivation therapy (ADT), the initial line of treatment for this disease, reduces circulating androgen levels to reduce tumor growth. While ADT is initially effective at reducing prostate cancer growth, after 2-3 years of treatment, most patients will progress to castration resistant prostate cancer (CRPC) which is defined as progression of prostate cancer in the presence of castrate levels of circulating testosterone. 3, 4 CRPC is often heralded by hyper-activated AR signaling leading to the transcription of downstream target genes and tumor growth despite insignificant levels of androgen present in the patient.
The most commonly prescribed first-line therapy for CRPC is docetaxel. Docetaxel functions by binding free tubulin in cells and causing the formation of stable microtubules which prevents depolymerization resulting in inhibition of mitosis and induction of apoptosis. [5] [6] [7] Like with many drugs, over time cancer cells develop resistance to docetaxel and prostate tumor growth will again proceed regardless of the presence of the drug.
Docetaxel resistance has been well studied and a number of contributing mechanisms have been identified. Several of these are related to increased activation of pathways involved in cell survival. [8] [9] [10] [11] [12] [13] Similarly, increased expression of inflammatory molecules such as interleukin (IL) 6, IL-8, chemokine ligand 2 (CCL2), transforming growth factor-β1 (TGF-β1), and macrophage inhibitory cytokine-1 (MIC-1) have been tied to promoting docetaxel resistance. [14] [15] [16] [17] [18] Conversely, reduced activity or expression of wild-type p53 is also linked to insensitivity to docetaxel. 19 Others have determined that docetaxel resistant prostate cancer cells have increased expression
and/or activity of multi-drug resistance proteins such as ABCB1 which excretes the docetaxel from the cells before it can elicit its therapeutic effect. 12, 20 Another 
| Western blot
Whole cell, nuclear, and cytosolic protein extracts were resolved on SDS-PAGE and proteins were transferred to nitrocellulose mem- 
| Statistical analysis
All data are presented as means ± standard error of the mean (SEM).
Significance is defined as P ≤ 0.05 as determined by one-way ANOVA in JMP.
3 | RESULTS
| Docetaxel resistant cells have increased expression of miR-181a
We have previously generated several docetaxel resistant prostate cancer cell sublines including TaxR from C4-2B and DU145-DTXR from DU145 cells. 20 We have identified that ABCB1 overexpression and activation confers resistance to both TaxR and DU145-DTXR cells. Although knock down of ABCB1 expression or inhibition of ABCB1 activity using small molecule inhibitors, such as elacridar, can resensitize these resistant cells to docetaxel treatment, the response is only partial, suggesting additional mechanisms are associated with docetaxel resistance. Studies investigating the role of miRNAs in docetaxel resistance have found that altered expression of several miRNAs, including miR-2, miR-200c, and miR-205, promotes resistance and disease progression. [23] [24] [25] In addition, studies have shown that overexpression of miRNA181 contributes to cell survival in the presence of doxorubicin and cisplatin in breast and cervical cancer. 26, 27 In order to determine if miR-181a is increased in docetaxel resistant cells compared to parental cell lines, rtPCR for miR-181a was performed on parental and docetaxel resistant cell lines. As seen in Fig. 1A , B, miR-181a expression is significantly increased in both TaxR (8.6-fold) and DU145-DTXR (7.4-fold) cells compared to parental C4-2B and DU145 cells, respectively.
| miR-181a overexpression induces docetaxel resistance
To test whether the increased expression of miR-181a has functional implications in prostate cancer cells, miR-181a was overexpressed in parental cells using miRNA mimics and knocked down in docetaxel resistant cells with miRNA inhibitors and cell number was determined following 48 h of treatment with docetaxel or vehicle control.
Overexpression of miRNA-181a significantly improved cell survival in the presence of increasing doses of docetaxel compared to the miR-mimic control in parental C4-2B cells ( Fig. 2A) . Conversely, knockdown of miR-181a resensitized docetaxel resistant TaxR cells to docetaxel treatment; at the highest docetaxel concentration (5 nM) no change in cell number was observed in control transfected cells, however, there was a 44% reduction in cell number in TaxR cells in response to 5 nM docetaxel when transfected with the miR-181a
antisense (Fig. 2B) . Likewise, parental DU145 cells had increased cell survival following transfection with miR-181a mimics in response to increased concentrations of docetaxel (Fig. 2C) and inhibition of miR181a resensitized docetaxel resistant DU145-DTXR cells to treatment (Fig. 2D) . Together, these data demonstrate that miR-181a promotes docetaxel resistance in prostate cancer and that targeting this miRNA can re-sensitize cells to docetaxel therapy.
| Knockdown of miR-181a resensitizes TaxR cells to cabazitaxel treatment
While cabazitaxel is known to be beneficial when administered postdocetaxel therapy, the survival benefit is modest, suggesting that there may be cross resistance between these two taxanes. 29 To respectively. When transfected with miR-181a mimics, cell number increased to 74%, 56%, and 39% of control in response to the same doses of cabazitaxel (Fig. 3A) . TaxR cells displayed cross resistance to cabazitaxel and knockdown of miR-181a in these cells successfully re-sensitized them to treatment with 1 or 5 nM cabazitaxel as seen by a reduction from 90% to 76% of control or from 65% to 43% of control respectively when miR-181a was inhibited (Fig. 3B ). These data suggest that similar resistance pathways occur between docetaxel and cabazitaxel and that inhibition of miR-181a could be beneficial for both.
| miR-181a does not alter ABCB1 expression or activity
Next we wanted to determine the mechanisms behind miR-181a induced docetaxel resistance. Previous data demonstrate that ATP Binding Cassette Subfamily B Member 1 (ABCB1) is significantly overexpressed in docetaxel resistant cells. 20 Furthermore, targeting ABCB1 expression or activity was observed to improve resistant cell response to docetaxel. 20, 30 Therefore, we decided to measure ABCB1 expression and efflux activity in response to miR-181a over and under expression in C4-2B parental and TaxR cells, respectively. As seen in Fig. 4A , modulating miR-181a expression had no effect on ABCB1 expression as determined by Western blot. Rhodamine assays were used to measure ABCB1 efflux activity. Overexpression of miR-181a
was incapable of inducing rhodamine efflux in C4-2B cells and miR181a knockdown in TaxR cells did not inhibit efflux (Fig. 4B ). These | 1023 data suggest that modulation of ABCB1 expression or activity is not a mechanism of action attributed to miR-181a-mediated resistance to docetaxel in prostate cancer.
| miR-181a inhibition induces p53 phosphorylation and apoptosis
Another potential mechanism associated with docetaxel resistance is loss of p53 phosphorylation in response to docetaxel. Knowing that ABCB1 was not involved in miR-181a mediated docetaxel resistance, we next investigated whether miR-18a could influence p53 and apoptosis. As seen in Fig. 5A , docetaxel treatment induced a 2.5-fold increase in phospho-p53 expression in parental C4-2B cells but not in TaxR cells, consistent with the previous report. 19 Knockdown of miR181a significantly increased p53 phosphorylation by 2.5-fold in both the presence and absence of docetaxel in TaxR cells. Supplementarily, knockdown of miR-181a in TaxR cells induced apoptosis which was further enhanced by co-treatment with docetaxel (Fig. 5B) .
Apoptosis was also assessed in p53-null PC3 prostate cancer cells in the presence or absence of docetaxel with either over-or underexpressed miR181a. As seen in Fig. 6A ,B, neither transfection with miR-181 mimics or miR-181 antisense altered the response of PC3 cells to docetaxel in regards to cell number (Fig. 6A) or induction of apoptosis (Fig. 6B ). These data, together with the data above, suggest that miR-181a functions, at least in part, by modulating p53 activity and inducing apoptosis to alter docetaxel sensitivity.
| DISCUSSION
In the presented study, we utilized docetaxel resistant prostate cancer cell lines to investigate the role of miR-181a in docetaxel resistance.
We found that miR-181a was significantly upregulated in two separate docetaxel resistant cell lines and that inhibition of its expression improved the response to docetaxel. Furthermore, overexpression of miR-181a in parental cell lines induced resistance.
miR-181a is a relatively well studied miRNA that has a wide range of known functions. The highest expression levels of miR-181a in a healthy setting are in the thymus and it is highly involved in T-cell function and sensitivity. 31, 32 Furthermore, miR-181a is known to be critical for organ development and differentiation, particularly through its modulation of zinc-finger proteins. [33] [34] [35] In regards to cancer, miR181a dysregulation is observed in several tumor types. Interestingly, both up-and down-regulation of miR-181a is associated with tumor formation as well as with drug resistance. Downregulation of miR181a has been observed in squamous lung cell carcinoma, oral squamous cell carcinoma, glioblastomas, and non-small-cell lung cancer. [36] [37] [38] [39] Conversely, breast cancer cells and hepatocellular carcinoma cells have increased expression of miR-181a. 40, 41 In hepatocellular carcinoma cells, increased expression of miR-181a induces resistance to sorafenib, a multi-kinase inhibitor, by suppressing RASSF1. 42 Additionally, miR-181a overexpression was also found to promote paclitaxel resistance in ovarian cancer cells. 43 Not only did miR-181a promote docetaxel resistance, but we found that its overexpression also induced resistance to cabazitaxel in sensitive cell lines and knockdown of miR-181a in docetaxel resistant cells (which are cross resistant to cabazitaxel) re-sensitized them to cabazitaxel treatment as well. Cabazitaxel is currently approved only for the treatment of patients who have previously undergone docetaxel treatment. 29, 44 The fact that cells that are resistant to docetaxel also display resistance to cabazitaxel is concerning for this patient population and makes identifying mechanisms of cross resistance important. The fact that inhibition of miR-181a
improved both response to docetaxel and cabazitaxel suggests that Therefore, we sought to determine whether miR-181a could alter ABCB1 expression or activity as part of its mechanism of action for inducing docetaxel resistance in prostate cancer cells. However, we found no change in either ABCB1 protein levels or drug efflux activity, suggesting that increased retention of docetaxel is not the mechanism by which miR-181a induces resistance in our model.
Other studies have found that in docetaxel resistant prostate cancer cells, treatment with docetaxel fails to initiate phosphorylation of p53 whereas in sensitive cells, docetaxel treatment causes a robust phosphorylation of p53. 19 miR-181a has been demonstrated to impact apoptosis and p53 signaling in previous studies in other tissue types.
Therefore, we next sought to determine whether miR-181a altering p53 signaling could be involved in the observed docetaxel resistance in our model. We found that inhibition of miR-181a alone was capable of inducing p53 phosphorylation in both the presence and absence of docetaxel. When apoptosis was measured, we observed that while miR181a inhibition on its own induced apoptosis, addition of docetaxel to the miR-181a inhibited cells increased apoptosis further still. The fact that there is increased apoptosis in response to docetaxel 6 Functional p53 is required for miR-181a mediated docetaxel resistance. p53-null PC3 cells were transfected with miR-181 mimics or antisense, along with the appropriate controls, and treated with 5 nM docetaxel (DTX). After 48 h treatment, cell number (A) was determined by Coulter counter and apoptosis (B) was determined by cell death ELISA. Results are presented as means ±SEM of three replicate experiments conducted in duplicate hairpin was more highly expressed than the mature strand, which suggests p53 may actually have a negative effect on mature miR181a. 48 Ongoing studies in our laboratory are seeking to determine a more precise role for miR-181a and p53 signaling in docetaxel resistant prostate cancer.
In summary, the presented study demonstrates that miR-181a is significantly upregulated in docetaxel resistant prostate cancer cell lines. Inhibition of miR-181a resensitizes resistant cell lines to docetaxel and overexpression of miR-181a promotes resistance to docetaxel therapy in resistant and sensitive cells respectively.
Furthermore, we determined that modulation of p53 phosphorylation is a likely mediator of miR-181a mediated docetaxel resistance. Data from this study are an important step forward toward understanding the mechanisms behind docetaxel resistance and will lead to improved treatment strategies for prostate cancer patients.
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